Omnicell, Inc. (NASDAQ:OMCL) Shares Bought by Connor Clark & Lunn Investment Management Ltd.

Key Points

• Connor Clark & Lunn Investment Management Ltd. increased its stake in Omnicell by 5.7%, acquiring an additional 24,301 shares, bringing its total ownership to 453,988 shares valued at approximately $15.87 million.
• Omnicell's stock is currently down 0.6%, trading at $30.83, with a 52-week range of $22.66 to $55.74, and a market capitalization of $1.42 billion.
• The company reported earnings of $0.45 per share for the last quarter, outperforming the consensus estimate of $0.30, with revenues of $290.56 million, reflecting a 5% year-over-year increase.

Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 5.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 453,988 shares of the company's stock after purchasing an additional 24,301 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 0.97% of Omnicell worth $15,871,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Victory Capital Management Inc. lifted its position in shares of Omnicell by 10.1% during the 1st quarter. Victory Capital Management Inc. now owns 1,680,347 shares of the company's stock valued at $58,745,000 after buying an additional 154,038 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Omnicell by 31.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company's stock valued at $73,127,000 after buying an additional 394,820 shares in the last quarter. Lazard Asset Management LLC lifted its position in shares of Omnicell by 81.6% during the 4th quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company's stock valued at $73,093,000 after buying an additional 737,536 shares in the last quarter. ArrowMark Colorado Holdings LLC lifted its position in shares of Omnicell by 4.9% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 1,196,990 shares of the company's stock valued at $53,290,000 after buying an additional 56,117 shares in the last quarter. Finally, Toronto Dominion Bank purchased a new position in shares of Omnicell during the 4th quarter valued at approximately $30,637,000. Institutional investors and hedge funds own 97.70% of the company's stock.

Omnicell Price Performance

Omnicell stock traded up $0.45 during trading hours on Friday, hitting $31.92. The stock had a trading volume of 145,288 shares, compared to its average volume of 565,894. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.42 and a quick ratio of 1.24. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of 63.83, a PEG ratio of 9.15 and a beta of 0.78. Omnicell, Inc. has a 1-year low of $22.66 and a 1-year high of $55.74. The stock's fifty day moving average is $29.44 and its two-hundred day moving average is $32.43.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.15. Omnicell had a return on equity of 4.27% and a net margin of 2.01%. The business had revenue of $290.56 million for the quarter, compared to the consensus estimate of $275.57 million. During the same period in the prior year, the business earned $0.51 earnings per share. The business's revenue was up 5.0% on a year-over-year basis. As a group, analysts predict that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

OMCL has been the topic of a number of research reports. Piper Sandler set a $55.00 price objective on Omnicell and gave the company an "overweight" rating in a report on Monday. Bank of America raised their price objective on Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a report on Friday, May 23rd. Wall Street Zen lowered Omnicell from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 9th. Benchmark decreased their price objective on Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Finally, Wells Fargo & Company raised their target price on Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a research note on Monday, July 21st. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $46.71.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.